Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.

Abstract

PURPOSE:

To report a case of familial exudative vitreoretinopathy (FEVR) rapidly resolved by intravitreal injection of bevacizumab.

METHODS:

A 36-year-old woman complained about floaters and visual field defect. Funduscopic examinations revealed retinal vessel anastomosis located between the equator and ora serrata in both eyes. The right eye was accompanied with slight vitreous hemorrhage. Since the patient declined retinal cryopexy for cosmetic reasons, intravitreal bevacizumab injections (1.25 mg/0.05 ml) were performed in both eyes.

RESULTS:

Treatment resulted in the rapid regression and the accelerated fibrosis of neovascular tissues. At 4-month follow-up in the right eye and 1-month follow-up in the left, no signs of systemic or ocular complications were detected.

CONCLUSIONS:

Intravitreal injection of bevacizumab may be considered as an alternative method in treating FEVR.

• Authors: Mizuki Tagami, Sentaro Kusuhara, Shigeru Honda, Yasutomo Tsukahara, Akira Negi
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 246 Issue 12 Pg. 1787-9 (Dec 2008) ISSN: 1435-702X [Electronic] Germany
• PMID: 18795314 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Adult
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Exudates and Transudates (metabolism)
• Eye Diseases (complications, drug therapy, genetics, metabolism)
• Female
• Fundus Oculi
• Humans
• Injections
• Neovascularization, Pathologic (etiology, pathology)
• Remission Induction
• Retinal Diseases (complications, drug therapy, genetics, metabolism)
• Retinal Hemorrhage (etiology, pathology)
• Retinal Vessels
• Time Factors
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Vitreous Body